Physician profile
Cameron Norman
NPI 1396150512
$1,464.59
in general payments reported to CMS, 2019-2025
14 companies · $482 in 2025
The $482 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $107 · 2022: $170 · 2023: $255 · 2024: $327 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.43 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $413.80 | 2023-2025 | Infuse |
| Biotissue Holdings INC. | $201.62 | 2025 | |
| Coopervision INC. | $192.88 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Mallinckrodt Hospital Products INC. | $142.92 | 2024 | Acthar |
| Alcon Vision LLC | $111.58 | 2019 | |
| Abbvie INC. | $94.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $62.93 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.94 | 2020 | |
| Dompe US, INC. | $50.82 | 2025 | Oxervate |
| Lombart Brothers, INC. | $45.80 | 2024 | Opd-III |
| Aerie Pharmaceuticals, INC. | $30.75 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $28.15 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abb Con-Cise Optical Group LLC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Norman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.